Thomas F. Reynolds

The cost of epilepsy in the United States: an estimate from population-based clinical and survey data.

Summary: Purpose: To provide 1995 estimates of the lifetime and annual cost of epilepsy in the United States using data from patients with epilepsy, and adjusting for the effects of comorbidities and socioeconomic conditions.

Cost of Epilepsy in the United States: A Model Based on Incidence and Prognosis

Summary: A model of the clinical course of epilepsy from onset until remission or death has been developed for six prognostic groups, including survival, use and cost of medical care, and time lost from work and housekeeping. The model has been used to generate preliminary estimates of the lifetime cost of epilepsy for a cohort of persons diagnosed in 1990 in the United States. The distribution of incident cases among prognostic groups is derived from epidemiologic studies of prognosis in epilepsy. Direct cost is estimated by multiplying nationally representative unit costs by the expected type and frequency of medical care use. The latter were derived by an expert panel, based on inferences from existing literature and on their own clinical experiences. Indirect cost is estimated based on lost earnings associated with projections of restricted activity days, excess unemployment, and excess mortality. Total lifetime cost in 1990 dollars of all persons with epilepsy onset in 1990 was estimated at

Sociodemographic disparities in epilepsy care: Results from the Houston/New York City health care use and outcomes study

3.0 billion, with indirect cost accounting for 62% of the total. Cost per patient ranged from

Methodological issues in estimating the cost of epilepsy.

4,272 for persons with remission after initial diagnosis and treatment to

Early treatment cost in epilepsy and how it varies with seizure type and frequency.

138,602 for persons with intractable and frequent seizures. Antiepileptic drug (AED) treatment is the most costly category of service. Different assumptions about the amount and type of drug administration cause major changes in overall cost estimates.

Socioeconomic status, health care use, and outcomes: persistence of disparities over time.

Purpose:  The purpose of this study was to identify sociodemographic disparities in health care use among epilepsy patients receiving care at different sites and the extent to which the disparities persisted after adjusting for patient characteristics and site of care.

Avoidable hospitalizations and socio-economic status in Galveston County, Texas

Changes in treatment alternatives and the emphasis on cost containment and managed care have increased the interest in information on the cost of epilepsy. The last comprehensive cost study in the USA was in 1975. That study estimated the national cost of epilepsy at

Estimating the Cost of Epilepsy

3.6 billion for 2.1 million cases. On a per patient basis the 1975 figure represents

Concordance of survey and billing data in a study of outpatient healthcare cost and utilization among epilepsy patients

7440 in 1995 US dollars,

Prevention of Herpes Simplex Virus Eye Disease: A Cost-effectiveness Analysis

1150 (15%) for direct treatment-related costs and